Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWC202405/DWC202313 and DWC202314 Combination Therapy in Essential Hypertension
NCT06671392Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DWC202314 in essential hypertension (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Change of Mean Sitting Systolic Blood Pressure at 8 weeks. Started Feb 2025; status: completed.
02
Drugs
DWC202314
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06671392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671392.